Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed

Simply Wall St.07-11 04:38

Intellia Therapeutics recently reported successful Phase 3 results for its in vivo CRISPR-based gene editing therapy Lonvo-z and outlined plans for a U.S. launch, marking a major step toward potential...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2650130333?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-07-11 04:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650130333","market":"hk","top_or_hot":-1,"title":"Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>Intellia Therapeutics recently reported successful Phase 3 results for its in vivo CRISPR-based gene editing therapy Lonvo-z and outlined plans for a U.S. launch, marking a major step toward potential...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-down-121-after-positive-phase\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch Plans - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-11 04:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-down-121-after-positive-phase><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Intellia Therapeutics recently reported successful Phase 3 results for its in vivo CRISPR-based gene editing therapy Lonvo-z and outlined plans for a U.S. launch, marking a major step toward potential...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-down-121-after-positive-phase\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-down-121-after-positive-phase","article_id":"2650130333","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-down-121-after-positive-phase","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2650130333","pubTimestamp":1783715895,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Intellia Therapeutics recently reported successful Phase 3 results for its in vivo CRISPR-based gene editing therapy Lonvo-z and outlined plans for a U.S. launch, marking a major step toward potential commercialization.\nThis clinical milestone positions Lonvo-z as one of the earlier gene-editing candidates moving toward the market, raising important questions about Intellia’s regulatory path, funding needs, and commercial execution.\nNext, we’ll examine how Lonvo-z’s positive Phase 3 outcome...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4556":"基因编辑","LU1861558580.USD":"日兴方舟颠覆性创新基金B","NTLA":"Intellia Therapeutics Inc","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"Intellia Therapeutics (NTLA) 在 Lonvo-z 第三阶段数据和 2027 年发布计划积极后下跌 12.1% - 发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1.5},"content_text":"Intellia Therapeutics recently reported successful Phase 3 results for its in vivo CRISPR-based gene editing therapy Lonvo-z and outlined plans for a U.S. launch, marking a major step toward potential commercialization. This clinical milestone positions Lonvo-z as one of the earlier gene-editing candidates moving toward the market, raising important questions about Intellia’s regulatory path, funding needs, and commercial execution. Next, we’ll examine how Lonvo-z’s positive Phase 3 outcome and 2027 U.S. launch ambitions could reshape Intellia’s existing investment narrative. Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.AdvertisementIntellia Therapeutics Investment Narrative RecapTo own Intellia Therapeutics, you need to believe one time CRISPR treatments like lonvo z can become meaningful, reimbursed therapies despite today’s losses and competition. The Phase 3 HAELO success and rolling BLA make U.S. approval and a 2027 launch the key near term catalyst, while execution on regulation, funding, and commercial rollout remains the biggest business risk, especially with the stock already trading on richer sales multiples than many peers. The most relevant recent development is Intellia’s rolling BLA submission for lonvo z, backed by detailed Phase 3 data showing an 87% reduction in HAE attacks and favorable safety. That filing, combined with the positive HAELO readout and published NEJM data, directly supports the current launch timeline and strengthens the near term catalyst, even as the follow on equity raise underlines ongoing cash burn and potential dilution concerns. But against the optimism around lonvo z, investors should also be aware of the risk that payer pushback on high upfront, one time gene editing treatments could... Read the full narrative on Intellia Therapeutics (it's free!)Intellia Therapeutics' narrative projects $909.0 million revenue and $77.6 million earnings by 2029. This requires 139.6% yearly revenue growth and a $472.2 million earnings increase from -$394.6 million today.Uncover how Intellia Therapeutics' forecasts yield a $26.63 fair value, a 72% upside to its current price.Exploring Other PerspectivesNTLA 1-Year Stock Price Chart Before this news, the most optimistic analysts were already modeling revenue near US$6.0 billion and earnings around US$1.9 billion by 2029, a far more bullish path than consensus and one that leans heavily on rapid lonvo z uptake despite reimbursement risk; your own view may sit very differently, so it is worth comparing these extremes as fresh trial and regulatory updates emerge.Explore 3 other fair value estimates on Intellia Therapeutics - why the stock might be a potential multi-bagger!The Verdict Is YoursDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Intellia Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.Our free Intellia Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Intellia Therapeutics' overall financial health at a glance.Contemplating Other Strategies?The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:Uncover the next big thing with 20 elite penny stocks that balance risk and reward.Outshine the giants: these 16 early-stage AI stocks could fund your retirement.AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650130333","isCrawlerRequest":true}